Novel Therapies Advance the Field of Genitourinary Cancers

2021 ◽  
Keyword(s):  
Novel Therapies ◽  
Genitourinary Cancers

ASCO-GU 2019: Metastasiertes Hormon-sensibles Prostatakarzinom

2019 ◽  
Vol 10 (02) ◽  
pp. 78-78
Author(s):  
Alexander Kretzschmar
Keyword(s):  
Phase Iii ◽  
Progressionsfreies Überleben ◽  
Genitourinary Cancers

Männer mit metastasiertem Hormon-sensiblen Prostatakarzinom (mHSPC) erreichen ein signifikant höheres medianes progressionsfreies Überleben anhand radiologischer Befunde (rPFS) und haben eine höhere objektive Responserate, wenn sie zusätzlich zu einer Androgen-depravierenden Therapie (ADT) auch Enzalutamid erhalten (jeweils p < 0,0001). Dies zeigt die randomisierte, doppelblinde Phase-III-Studie ARCHES (NCT02677896), deren Ergebnisse auf dem Genitourinary Cancers Symposium (ASCO GU) vorgestellt wurden.

High-Throughput Drug Screening of FDA-Approved Cancer Drugs Reveals Novel Therapies for Patients with Chordomas

2019 ◽  
Author(s):  
Philip Tatman ◽  
Anthony Fringuello ◽  
Denise Damek ◽  
Samy Youssef ◽  
Randy Jensn ◽  
...  
Keyword(s):  
High Throughput ◽  
Drug Screening ◽  
Novel Therapies ◽  
Cancer Drugs ◽  
High Throughput Drug Screening

Role of c-MET in Upper Aerodigestive Malignancies — From Biology to Novel Therapies

2005 ◽  
Vol 24 (3) ◽  
pp. 149-162 ◽  
Author(s):  
Sascha Dietrich ◽  
Radha Uppalapati ◽  
Tanguy Y. Seiwert ◽  
Patrick C. Ma
Keyword(s):  
Novel Therapies

Cancer Nanotheranostics: A Nanomedicinal Approach for Cancer Therapy and Diagnosis

2020 ◽  
Vol 20 (11) ◽  
pp. 1288-1299
Author(s):  
Paromita Kundu ◽  
Deepika Singh ◽  
Abhalaxmi Singh ◽  
Sanjeeb K. Sahoo
Keyword(s):  
Drug Delivery ◽  
Side Effects ◽  
Cancer Diagnosis ◽  
Specific Drug ◽  
Novel Therapies ◽  
Future Directions ◽  
Normal Tissues ◽  
Cancer Management ◽  
Single Probe ◽  
Therapy And Diagnosis

The panorama of cancer treatment has taken a considerable leap over the last decade with the advancement in the upcoming novel therapies combined with modern diagnostics. Nanotheranostics is an emerging science that holds tremendous potential as a contrivance by integrating therapy and imaging in a single probe for cancer diagnosis and treatment thus offering the advantage like tumor-specific drug delivery and at the same time reduced side effects to normal tissues. The recent surge in nanomedicine research has also paved the way for multimodal theranostic nanoprobe towards personalized therapy through interaction with a specific biological system. This review presents an overview of the nano theranostics approach in cancer management and a series of different nanomaterials used in theranostics and the possible challenges with future directions.

Fundamental study on clarification of brain molecular pathology of Nasu-Hakola disease

Impact ◽  
2019 ◽  
Vol 2019 (8) ◽  
pp. 24-26
Author(s):  
Jun-ichi Satoh
Keyword(s):  
Multiple Sclerosis ◽  
Human Brain ◽  
Clinical Research ◽  
Neurodegenerative Diseases ◽  
Molecular Pathology ◽  
Large Scale ◽  
Molecular Pathogenesis ◽  
Novel Therapies ◽  
Brain Pathology ◽  
Fundamental Study

Brain pathology expert Dr Jun-ichi Satoh, from the Department of Bioinformatics and Molecular Neuropathology of Meiji Pharmaceutical University in Tokyo, is drawing on his expertise on neurology and neuroimmunology to delve into some of the more complex diseases impacting the human brain. His knowledge and expertise have allowed him to direct his research interests to study neurodegenerative diseases, such as Alzheimer's disease (AD), and neuroinflammatory diseases, such as multiple sclerosis (MS), and the analysis of their molecular pathogenesis by using a bioinformatics approach. His current focus is on Nasu-Hakola disease (NHD), a disease whose rarity has posed significant barriers towards performing large-scale clinical research in order to understand what exactly causes this disease and develop effective novel therapies.

Sign in / Sign up

Export Citation Format

Share Document